ATHENA-1 (NCT05685173) **PHASE 1 ENROLLING**

Study of investigational REGN5837 + odronextamab in patients with **B-cell non-Hodgkin lymphomas**

Primary Objective: evaluate the safety, tolerability, and recommended phase 2 dose of REGN5837 with odronextamab in patients with aggressive B-NHL

PATIENTS WITH B-NHL (N≈91)

OPEN LABEL INTERVENTION

Step-up dosing schedule of REGN5837 (IV) + odronextamab (IV)

Primary Endpoints

Safety and tolerability

Secondary Endpoints

- Pharmacokinetics
- Immunogenicity
- Overall response rate[a,b]
- Complete response rate[a,b]
- Progression-free survival[a,b]
- Duration of response[a,b]
- Overall survival

FIND OUT MORE

Scan here to find out more about this study at https://clinicaltrials.gov/ct2/show/NCT05685173

This information is intended for investigators interested in open clinical trials.
The use of REGN5837 + odronextamab described herein is investigational and has not been evaluated by any regulatory authority.

[a]According to the Lugano Classification of response in malignant lymphoma. [b]Based on investigator assessment.
IV, intravenous; N, number of patients.

REGENERON®
MEDICAL AFFAIRS

ATHENA-1 (NCT05685173) **PHASE 1 ENROLLING**

REGN5837

An Investigational CD22xCD28 Bispecific Antibody
Simultaneously engages CD22 on cancer cells with CD28 on T cells[1]

+

ODRONEXTAMAB

An Investigational CD20xCD3 Bispecific Antibody
Simultaneously engages CD20 on malignant B cells and CD3 on cytotoxic T cells[1]

SELECTED INCLUSION CRITERIA[a]

- Documented CD20+ aggressive B-NHL with disease progression following at least 2 prior lines of therapy containing an anti-CD20 antibody and an alkylating agent
- Adequate bone marrow, renal, and hepatic function
- Measurable disease on cross sectional imaging
- 0 or 1 ECOG PS 0 or 1

SELECTED EXCLUSION CRITERIA[a]

- Prior allogeneic stem cell or solid organ transplantation
- Prior treatment with anti-CD20xCD3 antibodies
- Anti-lymphoma treatment within 5 half-lives or 14 days of first administration of study drug
- Radiotherapy within 14 days of first administration of study drug
- Diagnosis of MCL or primary CNS lymphoma
- Infections

For more information, visit www.clinicaltrials.gov or please call [+353 (0)61 533 400 or 844 REGN-MID].
NCT05685173
https://clinicaltrials.gov/ct2/show/NCT05685173

This information is intended for investigators interested in open clinical trials.
The use of REGN5837 + odronextamab described herein is investigational and has not been evaluated by any regulatory authority.

[a]Inclusion/exclusion criteria include a summary of selected criteria. Please review the complete study design on clinicaltrials.gov for complete details.

B-NHL, B-cell non-Hodgkin lymphoma; CD, cluster of differentiation; CNS, central nervous system; ECOG PS, Eastern Cooperative Oncology Group performance status; IV, intravenous; MCL, mantel cell lymphoma.

1. Wei J, et al. *Sci Transl Med*. 2022;14:eabn1082. 2. Smith EJ et al. *Sci Rep*. 2015;5:17943.

Current per clinicaltrials.gov as of December 21, 2023.

Odronextamab-EM-0010 v1.1 February 2024.

REGENERON®
MEDICAL AFFAIRS